Biosolution Co.Ltd Cash Flow Conversion Efficiency
Biosolution Co.Ltd cash flow conversion efficiency. Based on the latest financial reports, Biosolution Co.Ltd (086820) has a cash flow conversion efficiency ratio of 0.001x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩17.41 Million ≈ $11.80K USD) by net assets (₩26.31 Billion ≈ $17.83 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Biosolution Co.Ltd (2015–2024)
Cash flow conversion efficiency of Biosolution Co.Ltd from 2015 to 2024. This chart illustrates how Biosolution Co.Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View today's stock price for Biosolution Co.Ltd for real-time trading data and today's change.
Biosolution Co.Ltd Cash Flow Conversion Ratio Explained
Biosolution Co.Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Biosolution Co.Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Biosolution Co.Ltd ranked by their cash flow conversion efficiency. Also see 086820 market cap overview for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Catur Sentosa Adiprana Tbk
JK:CSAP
|
0.036x |
|
ATM Grupa S.A.
WAR:ATG
|
0.012x |
|
Min Aik Precision Industrial Co Ltd
TW:4545
|
-0.051x |
|
Aspire Mining Ltd
AU:AKM
|
-0.029x |
|
Rayence Co. Ltd
KQ:228850
|
0.009x |
|
Sirios Resources Inc.
V:SOI
|
-0.008x |
|
Precot Limited
NSE:PRECOT
|
0.013x |
|
Hwa Fong Rubber (Thailand) Public Company Limited
BK:HFT
|
0.045x |
Annual Cash Flow Conversion Efficiency for Biosolution Co.Ltd (2015–2024)
The table below shows the annual cash flow conversion efficiency of Biosolution Co.Ltd from 2015 to 2024. Review Biosolution Co.Ltd free cash flow ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩31.26 Billion ≈ $21.18 Million |
₩-2.29 Billion ≈ $-1.55 Million |
-0.073x | -242.66% |
| 2023-12-31 | ₩42.13 Billion ≈ $28.55 Million |
₩2.16 Billion ≈ $1.46 Million |
0.051x | +158.85% |
| 2022-12-31 | ₩43.78 Billion ≈ $29.67 Million |
₩-3.81 Billion ≈ $-2.58 Million |
-0.087x | -4808.31% |
| 2021-12-31 | ₩45.01 Billion ≈ $30.50 Million |
₩83.29 Million ≈ $56.44K |
0.002x | +105.12% |
| 2020-12-31 | ₩46.66 Billion ≈ $31.62 Million |
₩-1.69 Billion ≈ $-1.14 Million |
-0.036x | +33.31% |
| 2019-12-31 | ₩48.10 Billion ≈ $32.59 Million |
₩-2.61 Billion ≈ $-1.77 Million |
-0.054x | -359.07% |
| 2018-12-31 | ₩49.06 Billion ≈ $33.25 Million |
₩1.03 Billion ≈ $695.43K |
0.021x | +217.65% |
| 2017-12-31 | ₩4.42 Billion ≈ $2.99 Million |
₩-78.53 Million ≈ $-53.22K |
-0.018x | +94.74% |
| 2016-12-31 | ₩6.12 Billion ≈ $4.15 Million |
₩-2.07 Billion ≈ $-1.40 Million |
-0.338x | -24.26% |
| 2015-12-31 | ₩7.40 Billion ≈ $5.02 Million |
₩-2.02 Billion ≈ $-1.37 Million |
-0.272x | -- |
About Biosolution Co.Ltd
Bio Solution Co.,Ltd. develops, manufactures, and sells cell therapy products worldwide. The company offers CartiLife, an autologous chondrocyte cell-based therapy for the restoration of symptomatic and structural complications caused by articular cartilage defects; KeraHeal-Allo, a thermosensitive hydrogel-type allogenic keratinocyte cell-therapy product to promote re-epithelialization of deep 2… Read more